# Ipamorelin Research: The Newest Studies, Mechanism, and Human Data > Ipamorelin research, newest first: the 2024-2026 studies, the founding selectivity paper, the human pharmacokinetics, and the failed Phase 2 trial. Every claim cited. From the 2024 ferret cachexia study back to the 1998 founding paper — mechanism, human PK, and the trial that didn't work. ## Before the details This is the deep-dive page for ipamorelin research, and it runs newest-first because that is this site's whole angle. Quick map of what is below: the 2024-2026 papers (a ferret cachexia study, a fish hormone study, and three review articles); then the founding 1998 study that defined ipamorelin's signature selectivity; then the human pharmacokinetics (its roughly 2-hour half-life); then the bone-growth rat data; then the human trial that missed its mark; and finally the comparison sections people search for most — ipamorelin versus CJC-1295, sermorelin, and tesamorelin. A quick gloss before we start: a 'secretagogue' is just a compound that tells a gland to secrete something — here, growth hormone. Every number on this page maps to a numbered citation. ## The newest studies (2024-2026) The freshest published ipamorelin finding is the 2024 ferret study. Intraperitoneal ipamorelin (1-3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48-72 hours), but had no anti-emetic effect — it did not reduce the vomiting, whereas a brain-delivered dose of the related drug anamorelin cut acute emesis by 60% [5]. The takeaway: ipamorelin's weight-protective effect here was peripheral, and it does not double as an anti-nausea agent. In the same year, an aging-muscle study found that unacylated ghrelin protected against age-related loss of muscle mass and contractile strength [7]. The tested molecule was ghrelin, not ipamorelin — but it acts through the same ghrelin-receptor system, so it is honest mechanistic support for why researchers keep probing this pathway for sarcopenia, not proof ipamorelin does the same. A 2024 tilapia study added another thread: ipamorelin acetate dose-dependently raised serum LH and 11-ketotestosterone and stimulated germ-cell development, without changing GnRH fiber density — cross-species evidence that ghrelin-receptor activation can switch on the reproductive (hypothalamic-pituitary-gonadal) axis [13]. Three recent reviews place ipamorelin in context rather than testing it. A 2026 critical review of peptide use in sport flags ipamorelin as a widely promoted GH secretagogue with a short half-life that complicates anti-doping detection, and notes the real risks of uncontrolled GH-axis use [12]. A 2026 orthopaedics review classifies it as a GHS acting on IGF-1 and satellite-cell pathways, stresses that human safety data are absent, and calls for rigorous clinical evaluation before any orthopaedic adoption [14]. And a 2026 gerontology review groups ipamorelin with non-approved peptides that lack long-term safety data and validated monitoring frameworks, contrasting them with FDA-approved agents that carry large-trial safety profiles [15]. The pattern across all three: interest is real, human evidence is missing. ## Selectivity: the founding finding Ipamorelin's defining paper is from 1998. Across rat pituitary cells, anaesthetized rats, and conscious swine, it released GH potently — the pig ED50 was 2.3 nmol/kg, versus 3.9 for GHRP-6 — yet it did **not** raise ACTH or cortisol above the level seen with GHRH, even at doses more than 200-fold above its GH ED50 [1]. That made it the first highly GH-selective growth hormone secretagogue. In plain terms: it pushes the GH button hard while leaving the stress-hormone and prolactin buttons alone, which is exactly what older GHRPs could not do. This selectivity is the property every later study, and every marketing page, leans on. That receptor mechanism — agonism at GHS-R1a, the ghrelin receptor on pituitary somatotrophs — is unpacked in plain language on the [what does ipamorelin peptide do](/how-it-works) page. ## Human pharmacokinetics: the half-life everyone asks about The cleanest human data is pharmacokinetic. In healthy male volunteers (eight per dose level, five 15-minute IV infusions from 4.21 to 140.45 nmol/kg), ipamorelin showed dose-proportional kinetics with a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg [2]. The GH response was a single discrete pulse peaking around 40 minutes (0.67 h) after dosing. This is one of only a couple of human ipamorelin datasets in existence, and it is where the widely-quoted '~2 hour half-life' figure comes from. ## Bone and skeletal effects in rats The preclinical efficacy people cite most is skeletal. Subcutaneous ipamorelin at 18, 90, and 450 micrograms/day (split three times daily for 15 days) dose-dependently raised the longitudinal bone growth rate of adult female rats from 42 micrometers/day on vehicle to 44, 50, and 52 micrometers/day respectively — and it did so with **no** change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. That last detail matters: the skeletal effect appears partly local and GH-pulse-driven rather than purely IGF-1-mediated, which complicates the simple 'GH up, IGF-1 up, everything grows' story. ## The human trial that didn't work Honesty demands this section. Ipamorelin's only published Phase 2 RCT enrolled 114 adults undergoing bowel resection, dosed at 0.03 mg/kg IV twice daily for up to 7 days, and **missed its primary endpoint**: median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 on placebo, a difference that was not statistically significant (p=0.15) [3]. On the safety side, treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific signal in that short window. The trial is the defining human anchor for the compound, and the result is that efficacy was not demonstrated. No Phase 3 followed. ## The molecule as a scaffold A quieter research thread treats ipamorelin's structure as a starting point. Its backbone was used to build boron-rich peptide conjugates targeting the ghrelin receptor on cancer cells — a meta-carborane hexapeptide built on ipamorelin still activated GHS-R1a with high efficacy, showing the core's binding geometry tolerates bulky modification [8]. Separately, ipamorelin was one of several GHS scaffolds tested for inserting fluorine-18 to build a PET imaging probe for the ghrelin receptor; the best probe was actually a G-7039 analogue (IC50 ~69 nM, EC50 ~1.1 nM), and those affinity numbers belong to that analogue, not to ipamorelin itself [9]. These studies matter for receptor science, not for human use. ## Ipamorelin cjc-1295 The ipamorelin cjc-1295 pairing is the most-searched ipamorelin topic, so here is the straight version. The two are combined because they hit GH release through different doors: ipamorelin works on the ghrelin receptor (GHS-R1a), while CJC-1295 is a long-acting GHRH analog that works on the GHRH receptor. In healthy adults, a single subcutaneous dose of CJC-1295 produced dose-dependent 2- to 10-fold GH increases for six-plus days and 1.5- to 3-fold sustained IGF-1 elevation, while preserving the natural pulsing rhythm of GH — that study was on CJC-1295, not ipamorelin, and it is the published basis for the combination rationale [3]. Critically, no trial has ever tested the combination itself for any outcome. ## What is cjc-1295 ipamorelin What is cjc-1295 ipamorelin? It is a two-peptide pairing popular in research-use and clinic settings: CJC-1295 (a GHRH analog that provides a steady background signal) plus ipamorelin (a GHRP that provides a sharp, selective GH pulse). The logic is that a steady GHRH push plus a clean ghrelin-receptor pulse together raise GH more naturally than either alone. The single-agent pharmacology is published [1][2], but the duo as a unit has never been formally trialed — so 'cjc-1295 ipamorelin' is best understood as a community protocol built on separate building-block evidence, not an approved or tested product. ## Does cjc-1295 ipamorelin work Does cjc-1295 ipamorelin work? For raising GH and IGF-1, the individual pieces have measurable pharmacology — CJC-1295 produced multi-fold GH and IGF-1 elevation in healthy adults [3], and ipamorelin reliably releases a GH pulse [1][2]. For the outcomes people actually want — fat loss, muscle, anti-aging — there is no controlled human trial of the combination demonstrating any of it. So the mechanism works; the real-world benefit claims are unproven, and the human evidence for ipamorelin specifically is thin and partly negative [3]. ## Ipamorelin vs sermorelin Ipamorelin vs sermorelin comes down to which receptor each one hits. Ipamorelin is a GHRP — it acts on the ghrelin receptor (GHS-R1a) to fire a selective GH pulse without raising cortisol or prolactin [1]. Sermorelin is a GHRH analog — it acts on the GHRH receptor, mimicking the body's own growth-hormone-releasing hormone. They are not interchangeable; in fact they are mechanistically complementary, which is why GHRP-plus-GHRH stacks exist. One key difference in status: sermorelin has a regulatory history as an approved product, while ipamorelin has never been approved anywhere. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin is another GHRP-versus-GHRH-analog contrast. Tesamorelin is a stabilized GHRH analog with an actual approved human indication (HIV-associated lipodystrophy) and real human trial data behind it. Ipamorelin is a ghrelin-receptor GHRP whose human record is one small PK study and one failed Phase 2 trial [2][3], with no approval anywhere. So the honest framing is: tesamorelin is an approved drug studied in humans for a specific condition; ipamorelin is an investigational research peptide working through a different receptor, and the two should not be treated as substitutes. --- New studies first, plain English always — an independent ipamorelin reading list, never a clinic, a prescription, or a store.